Name: AAV-mir-GFP-Blank Control Virus (Serotype 4)
SKU: Am00104
Availability: InStock

<h2 dir="ltr">What Are AAV miRNA Negative Controls?</h2>
 MicroRNA (miRNA) research requires matched controls that enter the same delivery pathway as experimental constructs. AAV-delivered miRNA controls are particularly important for experiments in primary cells and in vivo models, where conventional transfection-based controls would not reflect the same delivery-related effects. The right miRNA control ensures accurate interpretation of miRNA-mediated effects. Choose a control matched to your expression and analysis workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Specific AAV miRNA Controls as blank control viruses used for precise tissue tropism matching.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
GFP-Tagged miRNA Control Viruses use fluorescent protein markers for successful transduction verification.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
pAAV-mir-GFP-hGH-amp Plasmids used for reliable cloning and feature ampicillin resistance and hGH polyadenylation&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
miRNA-OFF Blank Control Vectors used to validate miRNA inhibition specificity&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Ready-to-Use Control Virions used in comparative gene silencing for immediate use.
</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV miRNA Negative Control</h2>
 Delivery Pathway Matching When miRNA is delivered via AAV, the control must also be AAV-delivered &mdash; to account for capsid-mediated innate immune activation and viral DNA sensing effects that alter cellular transcription independently of the miRNA sequence itself. Mimic vs. Inhibitor Format Non-targeting miRNA mimic controls (gain-of-function studies) and non-targeting miRNA inhibitor controls (loss-of-function studies) require different control designs matching the experimental approach. Serotype and Promoter Matching The AAV miRNA control should share the same serotype and promoter as the experimental AAV-delivered miRNA construct to ensure comparable tissue tropism and expression timing. In Vivo vs. In Vitro Application AAV-delivered miRNA controls are particularly relevant for in vivo gain-of-function or loss-of-function studies, where AAV's broad tissue tropism and long-term expression make it the delivery method of choice. Validation of Off-Target Effects As with other RNAi-pathway controls, non-targeting designs should be validated to have minimal homology to known miRNA targets in the relevant species. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
When miRNA is delivered via AAV, the control should also be AAV-delivered to account for vector-related effects such as capsid interactions and cellular responses to the viral genome. This distinguishes AAV-based controls from transfection-derived controls, which do not capture AAV-specific delivery effects. Matching the serotype and promoter configuration of the control vector to the experimental construct helps ensure that observed phenotypes are attributable to the miRNA rather than differences in vector design. Researchers planning in vivo studies should obtain control and experimental AAV preparations with comparable production and quality metrics where possible, as differences in titer or purity can introduce unwanted variability. Including both an AAV-delivered control and, where appropriate, an untreated cohort can further aid interpretation of miRNA-specific effects. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team</a> at MBP Inc. to discuss the most suitable AAV miRNA control constructs for your study and request a quote tailored to your research requirements.

miRNA Control

Lentiviral Vector Amplification Protocol

AAV Infection Guideline

AAV Packaging Protocol

Selection-Drug Killing Curve

Lentivector Packaging Protocol

Lentivirus Infection Protocol

AAV-mir-GFP-Blank Control Virus (Serotype 4)

Unit Quantity

Titer

Storage Condition

Vector Map (Am00104)

Vector Map (Am00104a)

Shipping Condition

pAAV-mir-GFP-hGH-amp-Blank Control Virus (Serotype 4)

United States

Texas

mbpinc

AAV-mir-GFP-Blank Control Virus (Serotype 4)

SKU : Am00104